Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs
about
Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material.Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silicaOrdered mesoporous silicates as matrices for controlled release of drugs.Drug delivery from structured porous inorganic materials.Current developments in the therapy of protozoan infections.Solid dispersions, part II: new strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.Inorganic matrices: an answer to low drug solubility problem.Mesoporous silica formulation strategies for drug dissolution enhancement: a review.Crosslinked hydrogels-a promising class of insoluble solid molecular dispersion carriers for enhancing the delivery of poorly soluble drugs.Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.Hierarchical mesoporous silica nanofibers as multifunctional scaffolds for bone tissue regeneration.Self-Assembly of Pluronic F127-Silica Spherical Core-Shell Nanoparticles in Cubic Close-Packed Structures.High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.Development of Solid SEDDS, IV: Effect of Adsorbed Lipid and Surfactant on Tableting Properties and Surface Structures of Different Silicates.In vivo oral toxicological evaluation of mesoporous silica particles.Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.The phase (trans)formation and physical state of a model drug in mesoscopic confinement.(19) F NMR Spectroscopy as a Highly Sensitive Method for the Direct Monitoring of Confined Crystallization within Nanoporous Materials.Core-Shell Composite Hydrogels for Controlled Nanocrystal Formation and Release of Hydrophobic Active Pharmaceutical Ingredients.Building solids inside nano-space: from confined amorphous through confined solvate to confined 'metastable' polymorph.Nonlinear diffusion in two-dimensional ordered porous media based on a free volume theory.Enhanced dissolution and stability of artemisinin by nano-confinement in ordered mesoporous SBA-15 particles.Development of Novel Warfarin-Silica Composite for Controlled Drug Release.Drug Delivery System for Emodin Based on Mesoporous Silica SBA-15.Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications.Development of ternary solid dispersions with hydrophilic polymer and surface adsorbent for improving dissolution rate of carbamazepine.Pharmaceutically Active Supported Ionic LiquidsSilica-based multifunctional nanodelivery systems toward regenerative medicineFabrication of Heparinized Mesoporous Silica Nanoparticles as Multifunctional Drug Carriers
P2860
Q33770353-B7DFC37C-5FCC-4BB6-BBFF-D6F951221043Q36433678-5688EB9F-7237-46F8-B5BF-187B3AEFC988Q37822183-F7143F82-09F4-44AB-BF8B-2456EB794A99Q37849730-ACFD0AF8-2A0F-41E0-AF76-BAEE7D27D24BQ37883063-420C7F88-ADD7-4058-8255-310E85EE9DB7Q37932559-E8629EA0-5C52-4C9C-BD52-2DA97948B3E8Q38051672-CC2AA814-696C-47FA-9587-7DBF1BCEB839Q38628433-A69E565E-E9C4-4CDA-B7BB-12C4A1C76EA1Q38636974-E992E7E5-FF04-43E2-9A80-6A3064BDE36AQ38669102-8EE68892-8A86-4307-9E70-8E0A257EE49CQ39124597-B1AC4CB9-42CF-4F64-920A-5B35745E2C5CQ41813702-62F6AC65-76AF-4AF7-9185-F6FC93DDD434Q42661929-49C32BB8-5E1E-4632-AFEA-BF304B0B5CE2Q42866037-534193F3-8B27-4116-8E77-150C89D80D84Q44415530-DE769C69-0720-4CC4-BAC1-FA25BDE62695Q46232614-99D81CC3-A920-4A58-A51A-2D89FB830ECCQ46567604-C43B12F6-E8D7-4016-89E2-F4E62CACEB3CQ48210555-2BE6230A-9290-4777-96B2-DBC62C253434Q50804009-1826D245-879E-4EB0-8CF2-B4A6F91BFDE4Q50945176-1A293B3A-D372-488B-8AB2-F7B0F875B461Q51765401-099E5331-F63B-4F6E-B006-83C5FE6FA0F2Q53226398-50C4105F-5CC6-47D6-8288-F140BBF5D537Q53538350-FB158FCC-5631-4A13-A5A5-F671283BE421Q55087407-64781B68-6BFB-4FB8-9C1D-14FEF45D8AD3Q55265713-A38FC353-92B1-4D63-8CAD-69089916E366Q55510209-4D3FEE5F-3A50-482B-B26E-0968F8CCA427Q57086999-3FEFA59B-CDFF-4614-AF03-F6C7F41C86C3Q57367659-E6E50278-FF61-44B1-A649-77BE2B4F4F5BQ59008018-6FE4BD0D-4146-4779-8D87-0BA988366B04
P2860
Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@ast
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@en
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@nl
type
label
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@ast
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@en
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@nl
prefLabel
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@ast
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@en
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@nl
P2093
P50
P356
P1476
Ordered mesoporous silica mate ...... tform for poorly soluble drugs
@en
P2093
Guy Van den Mooter
Jan Van Humbeeck
Michiel Van Speybroeck
Randy Mellaerts
Thao Do Thi
Valéry Barillaro
P304
P356
10.1002/JPS.21638
P407
P577
2009-08-01T00:00:00Z